Company intelligence / Profile preview
NeuroVenti
Seoul, Korea, Southneuroventi.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NeuroVenti is developing multi-target small molecule drug candidates for neurodevelopmental and psychiatric conditions, including a phase II-ready candidate for autism spectrum disorder. Their lead candidate for ASD (NV01-A02) has received FDA Orphan Drug Designation.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
HLB Group (investment and strategic cooperation for epilepsy, AI-driven drug platform, and non-clinical CDRO services)
Beyond the preview
Go deeper on NeuroVenti.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroVenti.